Omega-3 Polyunsaturated Fatty Acids in Non-surgical Treatment of Periodontitis

Omega-3 Polyunsaturated Fatty Acids EPA and DHA as an Adjunct to Non-surgical Treatment of Periodontitis: a Randomized Clinical Trial

Periodontitis is a chronic multifactorial inflammatory disease that lead to the loss of supportive tissues around the teeth with gradual deterioration of masticatory function and esthetics, resulting eventually in the decrease of the quality of life. Host immune response triggered by bacterial biofilm is responsible for the chronic periodontal inflammation and ongoing tissue loss. Polyunsaturated fatty acids (PUFAs) omega-3 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have anti-inflammatory properties, thus may be used for the treatment of chronic inflammatory diseases. This study is aimed to evaluate the effect of dietary supplementation with PUFAs omega-3 in the patients with periodontitis stage III and IV.

Study Overview

• Status: Completed
• Conditions: Periodontitis; Therapeutics; Fatty Acids, Unsaturated
• Intervention / Treatment: Dietary supplement: fish oil; Procedure: SRP only

Detailed Description

Periodontitis is highly prevalent oral disease in humans affecting nearly 50% of the population worldwide. Periodontitis is multifactorial disease individually accelerated or decelerated by different factors. One of them, a bacterial biofilm, leads to dysbiosis and raise of Gram-negative bacteria.This results in the activations of immune response and clinical signs of periodontal tissue inflammation. Host modulation therapy seems to be an adequate concept for the treatment of periodontal diseases. The main assumption of this therapy is to reduce by-stander tissue destruction, to ensure rapid resolution of inflammation or even to promote regeneration of the periodontal tissues by modifying or down-regulating the destructive aspects of the host response and by up-regulating the protective or regenerative responses The goal of the present study was to assess the effect of high-dose omega-3 PUFAs EPA and DHA on the clinical outcome of non-surgical treatment of the patients with generalized periodontitis stage III and IV. It was presumed that dietary supplementation with high-dose EPA and DHA would have the potential to induce a measurable clinical outcome as a result of reduction of inflammation and minimizing tissue damage mediated by anti-inflammatory effect of omega-3 PUFAs. To address this issue, a randomized clinical trial was designed in which EPA and DHA were supplemented in adjunction to the standard periodontal therapy, scaling and root planning (SRP). Clinical outcomes of active versus control therapies were measured in addition to the quantifications of saliva cytokines, chemokines, subgingival biofilm composition and serum levels of lipids.

• Study Type: Interventional
• Enrollment (Actual): 50
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Poland
  • Lodz, Poland, 92-213
    • Department of Periodontology and Oral Mucosal Diseases

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• at least 18 scorable teeth (not including third molars),
• ≥4 teeth with PD ≥6 mm, CAL ≥5 mm,
• radiographic evidence of bone loss more than one-third of the root length,
• no periodontal treatment performed within last 6 months.

Exclusion Criteria:

• smoking,
• diabetes,
• any diseases or disorders that compromise wound healing,
• chronic inflammatory disease, history of radio- or chemotherapy,
• nonsteroidal anti-inflammatory drug (NSAIDs) intake > 3 days,
• use of antibiotics or corticosteroids 3 months prior to the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: SRP plus fish oil; Patients will receive scaling and root planing (SRP) supplemented with the dietary fish oil rich in omega-3 PUFAs: 2.6 g of EPA and 1.8 g DHA daily for 6 months.	Dietary supplement: fish oil; SRP will be supplemented with the dietary fish oil rich in omega-3 PUFAs EPA and DHA for 6 months. Fish oil (BioMarine Medical, 200 ml liquid), obtained from Tasmanian deep sea shark and Norwegian cod liver and sardine, anchovy and mackerel muscle, will be administered two times a day at a dose 10 ml. Daily dose of 20 ml provides 2.6 g of EPA and 1.8 g of DHA.; Other Names: BioMarine Medical; Procedure: SRP only; Scaling and root planing will be the only method of treatment.
Active Comparator: SRP alone; Patients will receive scaling and root planing (SRP) only.	Procedure: SRP only; Scaling and root planing will be the only method of treatment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in the percent of closed pockets	The percent of closed pockets (PD ≤ 4 mm and BOP-) at 3 and 6 months in relation to baseline	3 and 6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in the probing depth (PD)	Mean values of probing depth of all sites with initial PD ≥ 4 mm	3 and 6 months
Change in the clinical attachment level (CAL)	Mean values of clinical attachment level of all sites with initial PD ≥ 4 mm	3 and 6 months
Change in the bleeding on probing (BOP)	Percent of all sites with bleeding on probing	3 and 6 months
Change in the number of sites with PD ≥ 4 mm and BOP+	Mean values of number of sites with PD ≥ 4 mm and BOP+	3 and 6 months

Collaborators and Investigators

• Sponsor: Medical University of Lodz
• Investigators: Principal Investigator: Natalia Lewkowicz, prof., Medical University of Lodz

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2017
• Primary Completion (Actual): April 10, 2021
• Study Completion (Actual): September 30, 2021

Study Registration Dates

• First Submitted: June 22, 2020
• First Submitted That Met QC Criteria: July 15, 2020
• First Posted (Actual): July 20, 2020

Study Record Updates

• Last Update Posted (Actual): November 1, 2022
• Last Update Submitted That Met QC Criteria: October 28, 2022
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Keywords: periodontitis; non-surgical treatment; eicosapentaenoic acid; docosahexaenoic acid
• Additional Relevant MeSH Terms: Stomatognathic Diseases; Periodontal Diseases; Mouth Diseases; Periodontitis
• Other Study ID Numbers: RNN/251/17/KE

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No